查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1702013

2025 年至 2033 年癌症诊断市场报告（按产品、技术、应用、最终用户和地区）

Cancer Diagnostics Market Report by Product, Technology, Application, End User, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 145 Pages | 商品交期: 2-3个工作天内

价格

2024年全球癌症诊断市场规模达2,079亿美元。展望未来， IMARC Group预计到2033年市场规模将达到3,262亿美元，2025-2033年期间的成长率（CAGR）为4.88%。人们对疾病早期发现的认识不断提高、由于生活方式改变和遗传倾向而导致的癌症患病率上升、以及诊断技术的进步以加强对患者的护理是推动市场发展的一些主要因素。

癌症诊断可以识别并确定个别癌症的存在、类型和阶段。它包括一系列分析血液、组织和基因样本的技术，例如磁振造影 (MRI)、X 射线和实验室测试。它使医疗保健专业人员能够准确地检测和评估体内的癌症。它还使医疗保健提供者能够根据疾病的具体特征量身定制干预措施，从而优化患者的治疗结果。它有助于增强治疗决策并制定个人化的治疗策略。

目前，人们越来越倾向于采用非侵入性诊断方法，以最大限度地减少个人的不适和侵入性，这有助于市场的成长。除此之外，对经济高效且准确的诊断技术的需求不断增长，也促进了市场的成长。与此相符的是，人工智慧 (AI)、机器学习 (ML) 和资料分析在癌症诊断中的日益融合，以获得更快、更准确的结果，正在推动市场的成长。除此之外，一些国家的管理机构和卫生部门正在组织活动，向全世界大众传播有关癌症及其诊断的认知。此外，个人化医疗需求的不断增长以及全球医疗保健基础设施的不断改善，为市场带来了积极的前景。

癌症诊断市场趋势/驱动因素：

癌症发生率上升

由于生活方式的改变、环境因素、人口老化和遗传倾向等各种因素，癌症发生率有所上升。由于基因突变的累积和接触潜在致癌物的时间延长，人们罹患癌症的几率越来越大。此外，不良饮食习惯和缺乏体力活动等生活方式的改变也会增加罹患癌症的风险。除此之外，人们越来越倾向于早期发现以便有效治疗癌症。此外，为了避免个人出现进一步的併发症，对准确及时的癌症诊断的需求不断增长，这也促进了市场的成长。除此之外，医疗保健服务的日益普及也促进了市场的成长。

诊断技术的进步

製造商正在不断改进其诊断技术，以提供更高的敏感性、特异性和可近性。与此相符的是，分子和基因检测技术，例如下一代定序和液体活检，能够检测与不同类型癌症相关的特定生物标记。这些技术提供了对肿瘤特征的洞察并允许客製化治疗方法。除此之外，正子断层扫描-电脑断层扫描 (PET-CT) 和磁振造影 (MRI) 等影像方式的创新提供了更详细和准确的肿瘤可视化，有助于诊断和分期。此外，技术的不断进步提高了癌症诊断的精确度，这为市场前景带来了积极的影响。

人们对早期发现疾病的认识不断提高

消费者对早期癌症检测重要性的认识不断提高，促进了市场的成长。人们正在寻求定期筛检和诊断测试来监测他们的健康状况。此外，医疗保健提供者和组织正在组织许多活动，向公众宣传早期介入的好处，从而促进积极主动的健康寻求行为。除此之外，早期发现不仅可以改善治疗效果，还可以减轻晚期癌症相关的整体医疗负担。各国管理机构和医疗机构都在提供便利的筛检项目，并强调及时诊断癌症的重要性。这些措施鼓励人们定期进行癌症筛检，对市场产生了正面影响。

目录

第一章：前言

第二章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 次要来源
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章：执行摘要

第四章：简介

  • 概述
  • 主要行业趋势

第五章：全球癌症诊断市场

  • 市场概览
  • 市场表现
  • COVID-19的影响
  • 市场预测

第六章：市场区隔：依产品

  • 耗材
    • 关键部分
      • 抗体
      • 试剂盒和试剂
      • 探针
      • 其他的
  • 仪器
    • 关键部分
      • 病理学仪器
      • 成像仪器
      • 切片器械

第七章：市场区隔：依技术

  • 体外诊断试剂 (IVD) 测试
    • 关键部分
      • 聚合酶炼式反应（PCR）
      • 原位杂交（ISH）
      • 免疫组织化学（IHC）
      • 下一代定序（NGS）
      • 微阵列
      • 流式细胞仪
      • 免疫测定
      • 其他的
  • 影像学
    • 关键部分
      • 磁振造影（MRI）
      • 电脑断层扫描（CT）
      • 正子断层扫描（PET）
      • 乳房X光检查
      • 超音波
  • 切片技术

第 8 章：市场区隔：按应用

  • 乳癌
  • 肺癌
  • 大肠直肠癌
  • 黑色素瘤
  • 其他的

第九章：市场区隔：依最终用户

  • 医院和诊所
  • 诊断实验室
  • 其他的

第十章：市场细分：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场区隔：依国家

第 11 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 12 章：价值链分析

第 13 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 14 章：价格分析

第 15 章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Abbott Laboratories
    • Agilent Technologies Inc.
    • Becton Dickinson and Company
    • Bio-Rad Laboratories Inc.
    • F. Hoffmann-La Roche AG (Roche Holding AG)
    • GE HealthCare (General Electric Company)
    • Hologic Inc.
    • Illumina Inc.
    • Koninklijke Philips NV
    • Pfizer Inc.
    • Qiagen NV
    • Quest Diagnostics
    • Siemens Healthineers AG (Siemens AG)
    • Thermo Fisher Scientific Inc.
Product Code: SR112025A6322

The global cancer diagnostics market size reached USD 207.9 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 326.2 Billion by 2033, exhibiting a growth rate (CAGR) of 4.88% during 2025-2033. The growing awareness about early detection of disease, rising prevalence of cancer due to lifestyle changes and genetic predisposition, and advancements in diagnostics techniques to enhance patient care are some of the major factors propelling the market.

Cancer diagnostics identifies and determines the presence, type, and stage of cancer among individuals. It comprises a range of techniques and technologies, such as magnetic resonance imaging (MRI), X-rays, and laboratory tests, that analyze blood, tissue, and genetic samples. It allows healthcare professionals to accurately detect and assess cancerous growths within the body. It also enables healthcare providers to optimize patient outcomes by tailoring interventions to the specific characteristics of the disease. It assists in enhancing treatment decisions and developing personalized therapeutic strategies.

At present, the increasing preference for non-invasive diagnostic approaches that minimize discomfort and invasiveness among individuals is contributing to the growth of the market. Besides this, the rising demand for cost-effective and accurate diagnostics techniques is strengthening the market growth. In line with this, the increasing integration of artificial intelligence (AI), machine learning (ML), and data analytics in cancer diagnostics to enable quicker and more accurate results is propelling the growth of the market. Apart from this, governing agencies and healthcare authorities of several countries are organizing campaigns to spread awareness about cancer and its diagnostics among the masses worldwide. Furthermore, the growing demand for personalized medicines, along with the improving healthcare infrastructure around the world, is offering a positive market outlook.

Cancer Diagnostics Market Trends/Drivers:

Rising prevalence of cancer

There is a rise in the incidence of cancer due to various factors, such as lifestyle changes, environmental exposures, aging population, and genetic predisposition. People are increasingly suffering from cancer due to accumulated genetic mutations and longer exposure periods to potential carcinogens. In addition, lifestyle changes, such as poor diet and limited physical activity, is contributing to higher cancer risk. Apart from this, people are increasingly preferring early detection for effective treatment of cancer. Additionally, the rising demand for accurate and timely cancer diagnosis to avoid further complications among individuals is contributing to the growth of the market. Besides this, the increasing accessibility to healthcare services is bolstering the growth of the market.

Advancements in diagnostics techniques

Manufacturers are increasingly advancing their diagnostic technologies to offer greater sensitivity, specificity, and accessibility. In line with this, molecular and genetic testing techniques, such as next-generation sequencing and liquid biopsies, enable the detection of specific biomarkers associated with different types of cancer. These technologies provide insights into tumor characteristics and allow customized treatment approaches. Apart from this, innovations in imaging modalities, such as positron emission tomography-computed tomography (PET-CT) and magnetic resonance imaging (MRI), offer more detailed and accurate visualization of tumors that aid in diagnosis and staging. In addition, the continuous advancement in technologies enhances the precision of cancer diagnostics, which is offering a positive market outlook.

Growing awareness about early detection of diseases

Increasing consumer awareness about the importance of early cancer detection is bolstering the growth of the market. Individuals are seeking regular screenings and diagnostic tests to monitor their health conditions. Moreover, healthcare providers and organizations are organizing numerous campaigns to educate the public about the benefits of early intervention, thereby promoting proactive health-seeking behavior. Apart from this, early detection not only improves treatment outcomes but reduces the overall healthcare burden associated with advanced-stage cancer. Governing agencies and healthcare institutions of various countries are providing accessible screening programs and emphasizing the importance of timely cancer diagnosis. These initiatives encourage individuals to go for regular screening for cancer, which is positively influencing the market.

Cancer Diagnostics Industry Segmentation:

Breakup by Product:

  • Consumables
  • Antibodies
  • Kits and Reagents
  • Probes
  • Others
  • Instruments
  • Pathology-based Instruments
  • Imaging Instruments
  • Biopsy Instruments

Consumables comprise a wide range of products used in the process of cancer diagnostics. These include reagents, test kits, stains, and antibodies that are utilized in various diagnostic procedures, such as immunohistochemistry, molecular testing, and blood-based assays. In addition, consumables play a crucial role in facilitating accurate sample processing, analysis, and interpretation. The rising adoption of consumables due to the increasing demand for diagnostic testing in cancer care is bolstering the growth of the market.

Instruments refer to the equipment and devices employed to perform diagnostic tests and procedures. This category encompasses a diverse range of technologies, such as imaging equipment, laboratory equipment, and diagnostic platforms. Apart from this, there is a rise in the innovation of diagnostic instruments to improve the accuracy, speed, and efficiency of cancer diagnostics.

Breakup by Technology:

  • IVD Testing
  • Polymerase Chain Reaction (PCR)
  • In Situ Hybridization (ISH)
  • Immunohistochemistry (IHC)
  • Next-generation Sequencing (NGS)
  • Microarrays
  • Flow Cytometry
  • Immunoassays
  • Others
  • Imaging
  • Magnetic Resonance Imaging (MRI)
  • Computed Tomography (CT)
  • Positron Emission Tomography (PET)
  • Mammography
  • Ultrasound

Biopsy Technique

Imaging accounts for the majority of the market share

Imaging technologies involve the usage of advanced medical equipment to visualize internal structures and detect abnormalities within the body. Imaging techniques, such as magnetic resonance imaging (MRI), computed tomography (CT) scans, positron emission tomography (PET) scans, and ultrasound, provide detailed images of tumors and their size, location, and potential metastases. These technologies aid in tumor detection, staging, and treatment monitoring. In line with this, they play a vital role in guiding medical decisions, enabling precise surgical interventions, and evaluating treatment responses.

Breakup by Application:

  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Melanoma
  • Others

Breast cancer represents the largest market share

Breast cancer diagnostics comprise a wide range of methods for the early detection, diagnosis, and monitoring of breast tumors. Mammography is a widely used imaging technique that aids in detecting abnormalities, such as masses or microcalcifications. Besides this, biopsy procedures, such as core needle and fine-needle biopsies, provide tissue samples for pathological analysis that determine the nature and stage of the tumor. Molecular tests assess specific biomarkers like HER2/neu and estrogen receptor status. In addition, advanced imaging methods, such as breast MRI and molecular breast imaging, offer enhanced visualization and characterization of lesions.

Breakup by End User:

  • Hospitals and Clinics
  • Diagnostic Laboratories
  • Others

Hospitals and clinics hold the biggest market share

Hospitals serve as comprehensive healthcare institutions that are equipped with advanced diagnostic equipment and expert medical personnel. They offer a wide range of cancer diagnostic services and provide comprehensive treatment planning based on diagnostic findings. On the other hand, clinics involve specialized cancer centers that cater to outpatient needs and often focus exclusively on cancer care. They offer diagnostics, such as mammograms and consultations, which makes it convenient for patients to receive timely evaluations. Both hospitals and clinics play pivotal roles in delivering accurate and efficient diagnostics for cancer patients.

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

North America exhibits a clear dominance, accounting for the largest cancer diagnostics market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America held the biggest market share due to the improved healthcare infrastructure. Apart from this, the rising focus on early detection of diseases among individuals is contributing to the growth of the market in the region. In line with this, the increasing awareness about cancer, along with favorable reimbursement policies, is propelling the growth of the market. Besides this, the presence of key diagnostic technology manufacturers, research institutions, and a strong network of healthcare facilities is bolstering the growth of the market in the North America region.

Competitive Landscape:

Major players are investing in research and development (R&D) activities to develop innovative diagnostic technologies. This involves exploring new biomarkers, improving imaging modalities, and enhancing the accuracy of molecular and genetic testing methods. In addition, diagnostic companies are continuously updating their existing technologies and platforms and incorporating artificial intelligence (AI) and machine learning (ML) algorithms for more accurate interpretation of diagnostic results. Apart from this, many companies are engaging in collaboration with research institutions, universities, and healthcare providers to gain expert knowledge and can access patient data for validation and improvement of diagnostic tools. Furthermore, key players are introducing new diagnostic products and services that focus on improved sensitivity, specificity, and ease of use.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

  • Abbott Laboratories
  • Agilent Technologies Inc.
  • Becton Dickinson and Company
  • Bio-Rad Laboratories Inc.
  • F. Hoffmann-La Roche AG (Roche Holding AG)
  • GE HealthCare (General Electric Company)
  • Hologic Inc.
  • Illumina Inc.
  • Koninklijke Philips N.V.
  • Pfizer Inc.
  • Qiagen N.V
  • Quest Diagnostics
  • Siemens Healthineers AG (Siemens AG)
  • Thermo Fisher Scientific Inc.

Key Questions Answered in This Report

  • 1.What was the size of the global cancer diagnostics market in 2024?
  • 2.What is the expected growth rate of the global cancer diagnostics market during 2025-2033?
  • 3.What are the key factors driving the global cancer diagnostics market?
  • 4.What has been the impact of COVID-19 on the global cancer diagnostics market?
  • 5.What is the breakup of the global cancer diagnostics market based on the technology?
  • 6.What is the breakup of the global cancer diagnostics market based on the application?
  • 7.What is the breakup of the global cancer diagnostics market based on the end user?
  • 8.What are the key regions in the global cancer diagnostics market?
  • 9.Who are the key players/companies in the global cancer diagnostics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Cancer Diagnostics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Consumables
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Antibodies
      • 6.1.2.2 Kits and Reagents
      • 6.1.2.3 Probes
      • 6.1.2.4 Others
    • 6.1.3 Market Forecast
  • 6.2 Instruments
    • 6.2.1 Market Trends
    • 6.2.2 Key Segments
      • 6.2.2.1 Pathology-based Instruments
      • 6.2.2.2 Imaging Instruments
      • 6.2.2.3 Biopsy Instruments
    • 6.2.3 Market Forecast

7 Market Breakup by Technology

  • 7.1 IVD Testing
    • 7.1.1 Market Trends
    • 7.1.2 Key Segments
      • 7.1.2.1 Polymerase Chain Reaction (PCR)
      • 7.1.2.2 In Situ Hybridization (ISH)
      • 7.1.2.3 Immunohistochemistry (IHC)
      • 7.1.2.4 Next-generation Sequencing (NGS)
      • 7.1.2.5 Microarrays
      • 7.1.2.6 Flow Cytometry
      • 7.1.2.7 Immunoassays
      • 7.1.2.8 Others
    • 7.1.3 Market Forecast
  • 7.2 Imaging
    • 7.2.1 Market Trends
    • 7.2.2 Key Segments
      • 7.2.2.1 Magnetic Resonance Imaging (MRI)
      • 7.2.2.2 Computed Tomography (CT)
      • 7.2.2.3 Positron Emission Tomography (PET)
      • 7.2.2.4 Mammography
      • 7.2.2.5 Ultrasound
    • 7.2.3 Market Forecast
  • 7.3 Biopsy Technique
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Breast Cancer
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Lung Cancer
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Colorectal Cancer
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Melanoma
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Others
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Hospitals and Clinics
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Diagnostic Laboratories
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Abbott Laboratories
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Agilent Technologies Inc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 Becton Dickinson and Company
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Bio-Rad Laboratories Inc.
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 F. Hoffmann-La Roche AG (Roche Holding AG)
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 SWOT Analysis
    • 15.3.6 GE HealthCare (General Electric Company)
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
    • 15.3.7 Hologic Inc.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Illumina Inc.
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Koninklijke Philips N.V.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Pfizer Inc.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Qiagen N.V
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis
    • 15.3.12 Quest Diagnostics
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials
      • 15.3.12.4 SWOT Analysis
    • 15.3.13 Siemens Healthineers AG (Siemens AG)
      • 15.3.13.1 Company Overview
      • 15.3.13.2 Product Portfolio
      • 15.3.13.3 Financials
      • 15.3.13.4 SWOT Analysis
    • 15.3.14 Thermo Fisher Scientific Inc.
      • 15.3.14.1 Company Overview
      • 15.3.14.2 Product Portfolio
      • 15.3.14.3 Financials
      • 15.3.14.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Cancer Diagnostics Market: Major Drivers and Challenges
  • Figure 2: Global: Cancer Diagnostics Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Cancer Diagnostics Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Cancer Diagnostics Market: Breakup by Product (in %), 2024
  • Figure 5: Global: Cancer Diagnostics Market: Breakup by Technology (in %), 2024
  • Figure 6: Global: Cancer Diagnostics Market: Breakup by Application (in %), 2024
  • Figure 7: Global: Cancer Diagnostics Market: Breakup by End User (in %), 2024
  • Figure 8: Global: Cancer Diagnostics Market: Breakup by Region (in %), 2024
  • Figure 9: Global: Cancer Diagnostics (Consumables) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 10: Global: Cancer Diagnostics (Consumables) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 11: Global: Cancer Diagnostics (Instruments) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Global: Cancer Diagnostics (Instruments) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 13: Global: Cancer Diagnostics (IVD Testing) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Cancer Diagnostics (IVD Testing) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Cancer Diagnostics (Imaging) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Cancer Diagnostics (Imaging) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: Cancer Diagnostics (Biopsy Technique) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: Cancer Diagnostics (Biopsy Technique) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: Global: Cancer Diagnostics (Breast Cancer) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: Global: Cancer Diagnostics (Breast Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: Global: Cancer Diagnostics (Lung Cancer) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: Global: Cancer Diagnostics (Lung Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Global: Cancer Diagnostics (Colorectal Cancer) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Global: Cancer Diagnostics (Colorectal Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: Global: Cancer Diagnostics (Melanoma) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: Global: Cancer Diagnostics (Melanoma) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: Global: Cancer Diagnostics (Other Cancers) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: Global: Cancer Diagnostics (Other Cancers) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: Global: Cancer Diagnostics (Hospitals and Clinics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: Global: Cancer Diagnostics (Hospitals and Clinics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 31: Global: Cancer Diagnostics (Diagnostic Laboratories) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: Global: Cancer Diagnostics (Diagnostic Laboratories) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: Global: Cancer Diagnostics (Other End Users) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: Global: Cancer Diagnostics (Other End Users) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: North America: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: North America: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: United States: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: United States: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: Canada: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: Canada: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: Asia-Pacific: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: Asia-Pacific: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: China: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: China: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: Japan: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: Japan: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: India: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: India: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: South Korea: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: South Korea: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: Australia: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: Australia: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: Indonesia: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: Indonesia: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: Others: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: Others: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: Europe: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: Europe: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: Germany: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: Germany: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: France: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: France: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: United Kingdom: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: United Kingdom: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 65: Italy: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 66: Italy: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 67: Spain: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 68: Spain: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 69: Russia: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 70: Russia: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 71: Others: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 72: Others: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 73: Latin America: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 74: Latin America: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 75: Brazil: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 76: Brazil: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 77: Mexico: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 78: Mexico: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 79: Others: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 80: Others: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 81: Middle East and Africa: Cancer Diagnostics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 82: Middle East and Africa: Cancer Diagnostics Market: Breakup by Country (in %), 2024
  • Figure 83: Middle East and Africa: Cancer Diagnostics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 84: Global: Cancer Diagnostics Industry: SWOT Analysis
  • Figure 85: Global: Cancer Diagnostics Industry: Value Chain Analysis
  • Figure 86: Global: Cancer Diagnostics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Cancer Diagnostics Market: Key Industry Highlights, 2024 & 2033
  • Table 2: Global: Cancer Diagnostics Market Forecast: Breakup by Product (in Million USD), 2025-2033
  • Table 3: Global: Cancer Diagnostics Market Forecast: Breakup by Technology (in Million USD), 2025-2033
  • Table 4: Global: Cancer Diagnostics Market Forecast: Breakup by Application (in Million USD), 2025-2033
  • Table 5: Global: Cancer Diagnostics Market Forecast: Breakup by End User (in Million USD), 2025-2033
  • Table 6: Global: Cancer Diagnostics Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 7: Global: Cancer Diagnostics Market: Competitive Structure
  • Table 8: Global: Cancer Diagnostics Market: Key Players